Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorTONACIO, Adriana Coracini-
dc.contributor.authorPEDROSA, Tatiana do Nascimento-
dc.contributor.authorBORBA, Eduardo Ferreira-
dc.contributor.authorAIKAWA, Nadia Emi-
dc.contributor.authorPASOTO, Sandra Gofinet-
dc.contributor.authorFERREIRA FILHO, Julio Cesar Rente-
dc.contributor.authorBARROS, Marilia Mantovani Sampaio-
dc.contributor.authorLEON, Elaine Pires-
dc.contributor.authorLOMBARDI, Suzete Cleusa Ferreira Spina-
dc.contributor.authorMENDRONE JUNIOR, Alfredo-
dc.contributor.authorAZEVEDO, Adriana de Souza-
dc.contributor.authorSCHWARCZ, Waleska Dias-
dc.contributor.authorFULLER, Ricardo-
dc.contributor.authorYUKI, Emily Figueiredo Neves-
dc.contributor.authorLOPES, Michelle Remiao Ugolini-
dc.contributor.authorPEREIRA, Rosa Maria Rodrigues-
dc.contributor.authorBARROS, Percival Degrava Sampaio-
dc.contributor.authorANDRADE, Danieli Castro Oliveira de-
dc.contributor.authorMEDEIROS-RIBEIRO, Ana Cristina de-
dc.contributor.authorMORAES, Julio Cesar Bertacini de-
dc.contributor.authorSHINJO, Samuel Katsuyuki-
dc.contributor.authorMIOSSI, Renata-
dc.contributor.authorDUARTE, Alberto Jose da Silva-
dc.contributor.authorLOPES, Marta Heloisa-
dc.contributor.authorKALLAS, Esper Georges-
dc.contributor.authorSILVA, Clovis Artur Almeida da-
dc.contributor.authorBONFA, Eloisa-
dc.identifier.citationPLOS NEGLECTED TROPICAL DISEASES, v.15, n.11, article ID e0010002, 17p, 2021-
dc.description.abstractBackground Brazil faced a yellow fever(YF) outbreak in 2016-2018 and vaccination was considered for autoimmune rheumatic disease patients(ARD) with low immunosuppression due to YF high mortality. Objective This study aimed to evaluate, prospectively for the first time, the short-term immunogenicity of the fractional YF vaccine(YFV) immunization in ARD patients with low immunossupression. Methods and Results A total of 318 participants(159 ARD and 159 age- and sex-matched healthy controls) were vaccinated with the fractional-dose(one fifth) of 17DD-YFV. All subjects were evaluated at entry(D0), D5, D10, and D30 post-vaccination for clinical/laboratory and disease activity parameters for ARD patients. Post-vaccination seroconversion rate(83.7%vs.96.6%, p = 0.0006) and geometric mean titers(GMT) of neutralizing antibodies[1143.7 (95%CI 1012.3-1292.2) vs.731 (95%CI 593.6-900.2), p< 0.001] were significantly lower in ARD compared to controls. A lower positivity rate of viremia was also identified for ARD patients compared to controls at D5 (53%vs.70%, p = 0.005) and the levels persisted in D10 for patients and reduced for controls(51%vs.19%, p = 0.0001). The viremia was the only variable associated with seroconvertion. No serious adverse events were reported. ARD disease activity parameters remained stable at D30(p>0.05). Conclusion Fractional-dose 17DD-YF vaccine in ARD patients resulted in a high rate of seroconversion rate(> 80%) but lower than controls, with a longer but less intense viremia. This vaccine was immunogenic, safe and did not induce flares in ARD under low immunosuppression and may be indicated in YF outbreak situations and for patients who live or travel to endemic areas.eng
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2010/10749-0, 2017/14352-7, 2017/11516-9, 2018/16162-3]-
dc.description.sponsorshipConselho Nacional de Desenvolvimento Cientifico e Tecnologico-CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [306879/2018-2, 300248/2008-3, 300559/2009-7, 301411/2009-3, 303422/2015-7]-
dc.relation.ispartofPlos Neglected Tropical Diseases-
dc.titleImmunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseaseseng
dc.rights.holderCopyright PUBLIC LIBRARY SCIENCEeng
dc.subject.wosInfectious Diseaseseng
dc.subject.wosTropical Medicineeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng, Adriana de Souza:Fundacao Oswaldo Cruz Fdn, Inst Technol Immunobiol, FIOCRUZ, Biomanguinhos, Rio De Janeiro, Brazil-, Waleska Dias:Fundacao Oswaldo Cruz Fdn, Inst Technol Immunobiol, FIOCRUZ, Biomanguinhos, Rio De Janeiro, Brazil-
hcfmusp.publisher.citySAN FRANCISCOeng
hcfmusp.relation.referenceAvelino-Silva VI, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005219eng
hcfmusp.relation.referenceAzevedo LS, 2012, TRANSPL INFECT DIS, V14, P237, DOI 10.1111/j.1399-3062.2011.00686.xeng
hcfmusp.relation.referenceCampi-Azevedo AC, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-391eng
hcfmusp.relation.referenceCasey RM, 2019, NEW ENGL J MED, V381, P444, DOI 10.1056/NEJMoa1710430eng
hcfmusp.relation.referenceCook IF, 2008, VACCINE, V26, P3551, DOI 10.1016/j.vaccine.2008.04.054eng
hcfmusp.relation.referenceCroce E, 2017, VACCINE, V35, P1216, DOI 10.1016/j.vaccine.2017.01.048eng
hcfmusp.relation.referencede Fontbrune FS, 2018, J INFECT DIS, V217, P494, DOI 10.1093/infdis/jix564eng
hcfmusp.relation.referencede Verdiere NC, 2018, AIDS, V32, P2291, DOI 10.1097/QAD.0000000000001963eng
hcfmusp.relation.referenceFurer V, 2020, ANN RHEUM DIS, V79, P39, DOI 10.1136/annrheumdis-2019-215882eng
hcfmusp.relation.referenceHuber F, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tax082eng
hcfmusp.relation.referenceJohansson MA, 2014, T ROY SOC TROP MED H, V108, P482, DOI 10.1093/trstmh/tru092eng
hcfmusp.relation.referenceJuan-Giner A, 2021, LANCET, V397, P119, DOI 10.1016/S0140-6736(20)32520-4eng
hcfmusp.relation.referenceKohler S, 2012, EUR J IMMUNOL, V42, P2363, DOI 10.1002/eji.201142306eng
hcfmusp.relation.referenceLindsey NP, 2008, VACCINE, V26, P6077, DOI 10.1016/j.vaccine.2008.09.009eng
hcfmusp.relation.referenceMantel N, 2008, J VIROL METHODS, V151, P40, DOI 10.1016/j.jviromet.2008.03.026eng
hcfmusp.relation.referenceMartins RD, 2018, VACCINE, V36, P4112, DOI 10.1016/j.vaccine.2018.05.041eng
hcfmusp.relation.referenceMartins RD, 2015, HUM VACC IMMUNOTHER, V11, P2183, DOI 10.1080/21645515.2015.1022700eng
hcfmusp.relation.referenceMinisterio da Saude, 2018, MON PER SAZ FEBR AMA, V26, P1eng
hcfmusp.relation.referenceMonath TP, 2015, J CLIN VIROL, V64, P160, DOI 10.1016/j.jcv.2014.08.030eng
hcfmusp.relation.referenceMuniz LF, 2014, REV BRAS REUMATOL, V54, P349, DOI 10.1016/j.rbr.2014.04.002eng
hcfmusp.relation.referenceMuyanja E, 2014, J CLIN INVEST, V124, P3147, DOI 10.1172/JCI75429eng
hcfmusp.relation.referenceOliveira ACV, 2015, ARTHRITIS RHEUMATOL, V67, P582, DOI 10.1002/art.38960eng
hcfmusp.relation.referenceOPS, 2018, YELLOW FEV BRAZeng
hcfmusp.relation.referenceOrganization WH, 2018, CAUSALITY ASSESSMENT, Vsecondeng
hcfmusp.relation.referencePileggi GS, 2019, ADV RHEUMATOL, V59, DOI 10.1186/s42358-019-0056-xeng
hcfmusp.relation.referenceQuerec TD, 2009, NAT IMMUNOL, V10, P116, DOI 10.1038/ni.1688eng
hcfmusp.relation.referenceRoukens AH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027753eng
hcfmusp.relation.referenceSaad CGS, 2011, ANN RHEUM DIS, V70, P1068, DOI 10.1136/ard.2011.150250eng
hcfmusp.relation.referenceSilva ML, 2011, VACCINE, V29, P583, DOI 10.1016/j.vaccine.2010.08.046eng
hcfmusp.relation.referenceSimoes M, 2012, BIOLOGICALS, V40, P399, DOI 10.1016/j.biologicals.2012.09.005eng
hcfmusp.relation.referenceSociedade Brasileira de Reumatologia (SBR) Sociedade Brasileira de Imunizac Brasileira de Infectologia (SBI) Sociedade Brasileira de Medicina Tropical(SBMT), 2018, SOC NOTA TECN CONJ Veng
hcfmusp.relation.referenceValim V, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01382eng
hcfmusp.relation.referencevan Assen S, 2011, ANN RHEUM DIS, V70, P414, DOI 10.1136/ard.2010.137216eng
hcfmusp.relation.referenceVeit O, 2018, CLIN INFECT DIS, V66, P1099, DOI 10.1093/cid/cix960eng
hcfmusp.relation.referenceWHO, 2012, WORLD MALARIA REPORT 2012, P1eng
hcfmusp.relation.referenceWorld Hlth Org, 2017, VACCINE, V35, P5751, DOI 10.1016/j.vaccine.2017.06.087eng
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCM
Departamento de Clínica Médica - FM/MCM

Artigos e Materiais de Revistas Científicas - FM/MIP
Departamento de Moléstias Infecciosas e Parasitárias - FM/MIP

Artigos e Materiais de Revistas Científicas - FM/MPE
Departamento de Pediatria - FM/MPE

Artigos e Materiais de Revistas Científicas - FM/MPT
Departamento de Patologia - FM/MPT

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - HC/ICr
Instituto da Criança - HC/ICr

Artigos e Materiais de Revistas Científicas - HC/IOT
Instituto de Ortopedia e Traumatologia - HC/IOT

Artigos e Materiais de Revistas Científicas - LIM/03
LIM/03 - Laboratório de Medicina Laboratorial

Artigos e Materiais de Revistas Científicas - LIM/05
LIM/05 - Laboratório de Poluição Atmosférica Experimental

Artigos e Materiais de Revistas Científicas - LIM/17
LIM/17 - Laboratório de Investigação em Reumatologia

Artigos e Materiais de Revistas Científicas - LIM/31
LIM/31 - Laboratório de Genética e Hematologia Molecular

Artigos e Materiais de Revistas Científicas - LIM/36
LIM/36 - Laboratório de Pediatria Clínica

Artigos e Materiais de Revistas Científicas - LIM/48
LIM/48 - Laboratório de Imunologia

Artigos e Materiais de Revistas Científicas - LIM/56
LIM/56 - Laboratório de Investigação em Dermatologia e Imunodeficiências

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar

Files in This Item:
File Description SizeFormat 
art_TONACIO_Immunogenicity_and_safety_of_primary_fractionaldose_yellow_fever_2021.PDFpublishedVersion (English)1.34 MBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.